Results 141 to 150 of about 10,900 (261)

Estimate of Effectiveness of Palivizumab in the Prevention of Respiratory Syncytial Virus-Related Hospitalizations in a Cohort of Premature Children [PDF]

, 2006
As recomendações da Secção de Neonatologia da Sociedade Portuguesa de Pediatria (SNN-SPP) prevêem a profilaxia medicamentosa da infecção por vírus sincicial respiratório (VSR) com palivizumab em idades gestacionais (IG)inferiores a 30 semanas.
Costa, C, Dias Alves, A, Franco, J, Jorge, A, Queiroz, AM, Virella, D   +5 more
core  

Factores de riesgo identificados en niños que ingresaron a la unidad de cuidado intensivo pediátrico por bronquiolitis severa en el hospital occidente de Kennedy durante julio de 2007 a junio de 2009 [PDF]

, 2013
La bronquiolitis, infección de vías respiratorias bajas, genera un número importante de hospitalizaciones en menores de dos años, de estos, entre el 1 y el 5% requiere manejo en la Unidad de Cuidado Intensivo Pediátrico (UCIP) por la severidad de su ...
Pira Paredes, Luz Ángela, Socha Rodríguez, Jael Paola, Valero Garzón, Adriana, Ávila García, Ivonne Alejandra   +3 more
core  

Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is one of the major causes of respiratory tract infections among children. Until recently, the monoclonal antibody palivizumab was the only RSV prophylaxis available in Japan.
Naruhiko Ishiwada, Rina Akaishi, Yasuhiro Kobayashi, Kanae Togo, Naohiro Yonemoto, Moe Matsuo, Shinnosuke Kaneko, Amy W. Law, Kazumasa Kamei   +8 more
doaj   +1 more source

PIH2 Caress: The Canadian Registry of Synagis (2005-2010) [PDF]

, 2011
Paes, B.A., Mitchell, I., Li, A., Lanctot, K.L.   +3 more
core   +1 more source

MODERN POTENTIALITIES OF IMMUNOPROPHYLAXIS OF SEVERE COURSE OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH THE CONSEQUENCES OF PERINATAL PATHOLOGY

Педиатрическая фармакология, 2011
To a risk group of a heavy course of the respiratory syncytial viral (RSV) infection could be ascribed preterm infants, born before the 35th week of gestation inclusive, as well as children under 2 years old with the bronchopulmonary dysplasia or ...
L.S. Namazova-Baranova, I.V. Davydova, T.V. Turti, I.A. Belyaeva, V.V. Altunin   +4 more
doaj  

Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants. [PDF]

Hum Vaccin Immunother
Fullarton J, Paes B, Waghorne N, Keary I, Rodgers-Gray B, Carbonell-Estrany X.   +5 more
europepmc   +1 more source

Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants. [PDF]

Cost Eff Resour Alloc
Rodriguez-Martinez CE, Ordonez J, Carbonell-Estrany X, Fullarton J, Keary I, Rodgers-Gray B, D'Apremont I, Noyola DE, Ribeiro PA, Stein RT, Vain N, Tarride JE, Paes B.   +12 more
europepmc   +1 more source

The Effectiveness of Respiratory Syncytial Virus Prophylaxis Programme using Palivizumab in Preterm Infants: <i>A single institute retrospective study</i>. [PDF]

Sultan Qaboos Univ Med J
Al Mandhari H, Al Kendi S, Al-Balushi N, Bintaqi A, Al Saadi A, Abdellatif M.   +5 more
europepmc   +1 more source

Real-world impact of nirsevimab immunisation and maternal RSV vaccination against respiratory disease on emergency department attendances and admissions: a multinational retrospective analysis. [PDF]

Lancet Reg Health Eur
Perramon-Malavez A, Chiaretti A, Coma E, Craiu M, Foster S, Leonard P, Marlow R, Thors V, Martínez-Marcos M, Mendioroz J, Vila J, Creus-Costa A, Prats C, Roland D, Soriano-Arandes A, Williams TC, Buonsenso D.   +16 more
europepmc   +1 more source

Recommendations on Respiratory Syncytial Virus (RSV) Immunization Strategies for Infants and Young Children in Countries with Year-Round RSV Activity. [PDF]

Vaccines (Basel)
Cheah FC, Khoo EJ, Ali A, Ismail Z, Awang RA, Ng DC, Chan PWK, Ahmad Kamar A, Chua XY, Sam JI, Abdul Manaf MR, Kassim A.   +11 more
europepmc   +1 more source